Seminars in Hematology
Volume 49, Issue 1 , Pages 4-9, January 2012

Second Solid Tumors: Screening and Management Guidelines in Long-Term Survivors After Allogeneic Stem Cell Transplantation

  • Gerard Socié

      Affiliations

    • Hematology Transplantation, APHP Hospital Saint Louis and University Paris VII Denis Diderot, Paris, France
    • INSERM U728, Paris, France
    • Corresponding Author InformationAddress correspondence to Gerard Socié, MD, PhD, Hematology/Transplantation, Hospital Saint Louis, 1 Avenue Claude Vellefaux, 75475, Paris CEDEX 10, France
    • ,
  • J. Douglas Rizzo

      Affiliations

    • Center for International Blood and Marrow Transplant Research & Medical College of Wisconsin, Milwaukee, WI

With greater numbers of patients surviving long-term after allogeneic stem cell transplantation (SCT), second malignancies have increasingly been recognized. Secondary solid tumors, the most prevalent second malignancies after allogeneic SCT, are reviewed with particular emphasis on recent developments in the pathogenesis, early diagnosis, and treatment of these transplant-related complications.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Disclosure: none

PII: S0037-1963(11)00107-7

doi:10.1053/j.seminhematol.2011.10.013

Seminars in Hematology
Volume 49, Issue 1 , Pages 4-9, January 2012

Article Tools